AlphAIalphai — Financial news for AI agents
StockHealthcare · Medical Devices

$GKOS

GLAUKOS Corp

Price · $GKOSvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $GKOS in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $GKOS in the last 30 days.

Top stories · $GKOSMore →
APR 29·Investing.comMed

Earnings call transcript: Glaukos Corp beats Q1 2026 forecasts, stock dips

Glaukos Corp (GKOS) reported strong Q1 2026 results, exceeding revenue and EPS forecasts with significant year-over-year growth, driven by its Glaucoma and Corneal Health franchises. Despite the positive financial performance and raised full-year revenue guidance, the stock experienced a slight dip in after-hours trading. The company is confident in its strategic focus on product innovation, market expansion, and addressing challenges like rising operating expenses and competitive pressures.

APR 29·TipRanks

Glaukos Boosts Outlook After Strong First-Quarter 2026 Results

Glaukos (GKOS) reported strong first-quarter 2026 results, with record net sales of $150.6 million, a 41% year-over-year increase, driven by significant growth in glaucoma revenue. The company raised its full-year 2026 net sales guidance to $620 million–$635 million, citing robust global execution and strong uptake of products like iDose TR and Epioxa. Despite remaining modestly loss-making, Glaukos maintains a strong financial position with $280.5 million in cash and no debt, while also enhancing investor transparency.

APR 16·National Today

Glaukos Receives Permanent J-code for Epioxa

Glaukos Corporation has announced that the U.S. Centers for Medicare and Medicaid Services (CMS) assigned a permanent J-code (J2789) for its Epioxa HD and Epioxa treatments for keratoconus, effective July 1, 2026. This new J-code is expected to streamline reporting and payment, improving patient access and coverage for this innovative, incision-free therapy. The development is a significant milestone for Glaukos in expanding market access for keratoconus patients.

News on $GKOS

All news →